Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.
|Recent News||More >>|
Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
Ascendis Pharma A/S Announces Upcoming Investor Presentations
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Primary IR Contact|
|Scott T. Smith|
Chief Financial Officer
Data provided by Nasdaq. Minimum 15 minutes delayed.